Abstract
Purpose
To date, no detailed study of the changes in the image-defined risk factors (IDRFs) after neoadjuvant chemotherapy has been performed. The aim of this study was to investigate the effect of chemotherapy on IDRFs for stage L2 neuroblastomas.
Methods
Fifteen stage L2 patients treated by neoadjuvant chemotherapy were selected. Changes after chemotherapy in the number of positive IDRFs, tumor size and major surgical complications were evaluated.
Results
All IDRFs disappeared after chemotherapy in four patients (group A) and a reduction in the number of IDRFs, but not disappearance, after chemotherapy was observed in five patients (group B). No change in the number of IDRFs after chemotherapy was observed in six patients (group C). All tumors in groups A shrunk to <20 % of the pretreatment volume. Major surgical complications were observed in one of two, two of three and three of five patients who underwent tumor excision in groups A, B and C, respectively.
Conclusions
Only 27 % of the tumors with IDRFs became negative for IDRFs after chemotherapy. For negative IDRFs, tumors should shrink to <20 % of the volume at the time of diagnosis. Stage L2 tumors may have a potential risk for surgery even after neoadjuvant chemotherapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Evans AE, Silber JH, Shpilsky A, D’Angio GJ (1996) Successful management of low-stage neuroblastoma without adjuvant therapies: a comparison of two decades, 1972 through 1981 and 1982 through 1992, in a single institution. J Clin Oncol 14(9):2504–2510
Hero B, Simon T, Spitz R, Ernestus K, Gnekow AK, Scheel-Walter HG, Schwabe D, Schilling FH, Benz-Bohm G, Berthold F (2008) Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J Clin Oncol 26(9):1504–1510. doi:10.1200/JCO.2007.12.3349
Iehara T, Hamazaki M, Tajiri T, Kawano Y, Kaneko M, Ikeda H, Hosoi H, Sugimoto T, Sawada T, Japanese Infantile Neuroblastoma Cooperative Study G (2013) Successful treatment of infants with localized neuroblastoma based on their MYCN status. Int J Clin Oncol 18(3):389–395. doi:10.1007/s10147-012-0391-y
Matthay KK, Perez C, Seeger RC, Brodeur GM, Shimada H, Atkinson JB, Black CT, Gerbing R, Haase GM, Stram DO, Swift P, Lukens JN (1998) Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children’s Cancer Group study. J Clin Oncol 16(4):1256–1264
Cozzi DA, Mele E, Ceccanti S, Natale F, Clerico A, Schiavetti A, Dominici C (2013) Long-term follow-up of the “wait and see” approach to localized perinatal adrenal neuroblastoma. World J Surg 37(2):459–465. doi:10.1007/s00268-012-1837-0
Nuchtern JG, London WB, Barnewolt CE, Naranjo A, McGrady PW, Geiger JD, Diller L, Schmidt ML, Maris JM, Cohn SL, Shamberger RC (2012) A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children’s Oncology Group study. Ann Surg 256(4):573–580. doi:10.1097/SLA.0b013e31826cbbbd
Yoneda A, Oue T, Imura K, Inoue M, Yagi K, Kawa K, Nishikawa M, Morimoto S, Nakayama M (2001) Observation of untreated patients with neuroblastoma detected by mass screening: a “wait and see” pilot study. Med Pediatr Oncol 36(1):160–162
Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, Kaneko M, London WB, Matthay KK, Nuchtern JG, von Schweinitz D, Simon T, Cohn SL, Pearson AD (2009) The International Neuroblastoma Risk Group (INRG) staging system: an INRG task force report. J Clin Oncol 27(2):298–303. doi:10.1200/JCO.2008.16.6876
Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, Mosseri V, Simon T, Garaventa A, Castel V, Matthay KK (2009) The International Neuroblastoma Risk Group (INRG) classification system: an INRG task force report. J Clin Oncol 27(2):289–297. doi:10.1200/JCO.2008.16.6785
Yoneda A, Nishikawa M, Uehara S, Oue T, Usui N, Inoue M, Fukuzawa M, Okuyama H (2015) Can image-defined risk factors predict surgical complications in localized neuroblastoma? Eur J Pediatr Surg. doi:10.1055/s-0035-1566100
Brisse HJ, McCarville MB, Granata C, Krug KB, Wootton-Gorges SL, Kanegawa K, Giammarile F, Schmidt M, Shulkin BL, Matthay KK, Lewington VJ, Sarnacki S, Hero B, Kaneko M, London WB, Pearson AD, Cohn SL, Monclair T (2011) Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project. Radiology 261(1):243–257. doi:10.1148/radiol.11101352
Simon T, Hero B, Benz-Bohm G, von Schweinitz D, Berthold F (2008) Review of image defined risk factors in localized neuroblastoma patients: results of the GPOH NB97 trial. Pediatr Blood Cancer 50:965–969. doi:10.1002/pbc.21343
Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, Gerbing RB, London WB, Villablanca JG (2009) Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children’s oncology group study. J Clin Oncol 27(7):1007–1013. doi:10.1200/JCO.2007.13.8925
Acknowledgments
The authors appreciate the JNBSG members for their helpful discussions. This work was supported by the Practical Research for Innovative Cancer Control from the Japan Agency for Medical Research and Development, AMED.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yoneda, A., Nishikawa, M., Uehara, S. et al. Can neoadjuvant chemotherapy reduce the surgical risks for localized neuroblastoma patients with image-defined risk factors at the time of diagnosis?. Pediatr Surg Int 32, 209–214 (2016). https://doi.org/10.1007/s00383-016-3858-5
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00383-016-3858-5